Healthcare >> CEO Interviews >> October 6, 2023

Interview with the CEO: Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

Barrow, Robert
Robert Barrow is the Chief Executive Officer and Board Director of Mind Medicine (MindMed) Inc. Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. After joining MindMed as Chief Development Officer in January 2021, he was named CEO in June 2021. Mr. Barrow previously served as Director of Drug Development & Discovery at Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona’s development programs. Prior to joining Usona, Mr. Barrow served as Chief Operating Officer of Olatec Therapeutics, LLC, a private, clinical-stage biopharmaceutical company, where he oversaw the execution of numerous early- and late-stage clinical trials in the fields of analgesics, rheumatology, immunology and cardiovascular disease. In addition, he has been responsible for the design and execution of preclinical research programs for new molecular entity drugs in brain health disorders. Mr. Barrow has also served as both a technical and business adviser to numerous pharmaceutical organizations ranging from startups to Fortune 500 companies. Profile
Word count: 3,430

TWST: MindMed is the first publicly traded psychedelics company in the world. How did you get to this point?

Mr. Barrow: Yes, it’s been an